To Get Full Access :

Fruzaqla

Fruzaqla is a once-daily oral treatment for metastatic colorectal cancer in adults who have already tried other therapies. It inhibits VEGF receptors to slow tumor growth and improve survival.

Molecule Details :

  • Molecule Name :

    Fruquintinib
  • Innovator :

    TAKEDA PHARMACEUTICALS USA INC
  • Approval Date :

    08-Nov-23
  • NCE-1 Date :

    08-Nov-27
  • NCE Date :

    08-Nov-28
  • Dosage Form :

    Capsule
  • Strength :

    1mg & 5mg
  • Therapeutic Category :

    Anticancer
  • Revenue ($M) :

    354

Year-wise Projected Sales ($M) :

  • 2025 :

    368
  • 2026 :

    426
  • 2027 :

    480
  • 2028 :

    470
  • 2029 :

    467
  • 2030 :

    487
  • 2031 :

    508
Looking for this molecule for your next clinical research? Access regulatory-compliant comparators with assured timelines—delivered reliably through our global network.

Why Choose Spring Bio Solution?

Supported 1000+ Clinical Trials globally

Provides services across regulatory, legal & clinical research

Unmatched intelligence on batches, expiry, spacing, and historical data from innovators

Integrated CRO Services as part of our offerings

Insights on global pricing for smarter clinical trial supply decisions 


Login NCE Grid

Register NCE Grid

Are you sure want to logout from NCE Grid?